Zhang Cathy’s Post

𝗜𝗦𝗡 𝗩𝗜𝗗𝗘𝗢 𝗔𝗕𝗦𝗧𝗥𝗔𝗖𝗧 𝗦𝗘𝗥𝗜𝗘𝗦: Systems analyses of the Fabry kidney transcriptome and its response to enzyme replacement therapy identified and cross-validated enzyme replacement therapy-resistant targets amenable to drug repurposing. ➡️ https://ow.ly/yLWH50QnwzY #VideoAbstract by Dilushi Wijaratne and Augusto Santos jr. #ThisIsISN – Advancing kidney health worldwide. Together.

A new FAQ video module featuring Claudia D. Rivera-Salas, DNP, APRN, NP-C, is now live! Dive into the variability in JAK enzyme inhibition across different JAK inhibitors and explore their potential clinical implications. Watch now for valuable insights at https://loom.ly/eLeaCqQ!

🔬 Explore the Future of At-Home STI Testing 🏡 With STI rates rising globally, accessible and accurate diagnostics are crucial. This Meridian Bioscience Inc. Webinar examines key advancements making at-home STI testing a reality: ✅ Molecular techniques for direct detection from crude samples ✅ High-performing immunoassay reagents for rapid tests ✅ Trends driving expansion of self-collection/home-testing Learn about innovative solutions overcoming barriers like stigma and enabling early detection of asymptomatic infections. This key webinar is now OnDemand! - https://lnkd.in/eT-MDS3r Don't miss this insightful look into the evolving STI testing landscape! #MeridianBioScience #PracticalPatientCare #STITesting #MolecularDiagnostics #SexualHealth

New video! How do JAK inhibitors differ? I’ll explain 🙂

Photosensitivity characterizes porphyria cutanea tarda,with differentiation from other porphyrias identified by deficiency of uroporphyrinogen III decarboxylase enzyme; enzymatic activity < 20% prior to observation of clinical symptoms.(NIH 5/4/2021)

#ArticlesInPress: The #FXYD1 protein plays a protective role against pulmonary #hypertension and #arterial remodelling via redox and inflammatory mechanisms. (Thomas S Hansen et al.) https://ow.ly/RH7l50QuoJz #pulmonaryhypertension #nitricoxide #FXYD1

What do you know about #Lpa? Discover the ground-breaking insights into #Lpa's complex atherogenicity in the latest study led by @DzoboKim from the @KroonLab, unveiling the significant impact of #Lpa-associated diacylglycerols and lysophosphatidic acid on monocyte inflammation @Lpa_doc https://lnkd.in/ejDe__pm

Now that the Proceedings of the 3rd IPFA/EBA Symposium held earlier this month are now available online, I'm making available the video of my own presentation, which I had to record as personal issues precluded my presence. in this talk, I draw on the methodology developed by Jeff Stonebraker and myself over the past years to estimate the Latent Therapeutic Demand for several of the evidence-based indications for immunoglobulin. This shows that current usage in Europe still lags substantially behind this demand, and may be expected to increase further as diagnostic capacity improves and access to treatment is attained. There is a tendency in some quarters to ascribe the demand for immunoglobulin to off-label use, I consider this to be a myth mouthed by those responsible for ensuring the supply of the product. Increasing plasma supply, enhancing production yields and using alternatives as these become available are the routes to immunoglobulin sufficiency. https://lnkd.in/gnkjER2K

Attention must focus on taking the necessary actions to ensure a sustainable supply of IGs are available - without interruption - for those whose physicians see that their health will benefit from it. Preventing some patients from receiving treatment is not the answer to this challenge. Let’s double down on the right solutions.

#DiagnosticEfficiency👩🏼🔬 Learn about our turbidimetric Retinol-Binding Protein #RBP assay in this webinar focusing on clinical utility. The diagnostic value lies in altered levels of circulating RBP in many conditions👉 https://lnkd.in/dyT9upM4